OBJECTIVE: To provide a systematic review of the literature regarding the efficacy of anti-inflammatory drugs in three major mental disorders [major depressive disorder (MDD), schizophrenia and bipolar disorders]. METHOD: Four databases were explored, without any year or language restrictions. The baseline search paradigm was limited to open-labelled clinical and randomized controlled trials (RCTs). RESULTS: Four major classes of anti-inflammatory drugs were identified, namely polyunsaturated fatty acids (PUFAs), cyclooxygenase (COX) inhibitors, anti-TNFalpha and minocycline. Effectiveness and benefit/risk ratio of each class in MDD, bipolar disorders and schizophrenia was detailed when data were available. Several meta-analyses indicated effectiveness of PUFAs in MDD with a good tolerance profile. One meta-analysis indicated that COX-2 specific inhibitors showed effectiveness in schizophrenia. Anti-TNFalpha showed important effectiveness in resistant MDD with blood inflammatory abnormalities. Minocycline showed effectiveness in schizophrenia. CONCLUSION: Polyunsaturated fatty acids seem to have the best benefit/risk ratio profile but proved their effectiveness only in MDD. A number of anti-inflammatory drugs are available as adjunct treatment for treatment-resistant patients with MDD, schizophrenia and bipolar disorder. If used with caution regarding their possible side-effects, they may be reasonable therapeutic alternatives for resistant symptomatology.
OBJECTIVE: To provide a systematic review of the literature regarding the efficacy of anti-inflammatory drugs in three major mental disorders [major depressive disorder (MDD), schizophrenia and bipolar disorders]. METHOD: Four databases were explored, without any year or language restrictions. The baseline search paradigm was limited to open-labelled clinical and randomized controlled trials (RCTs). RESULTS: Four major classes of anti-inflammatory drugs were identified, namely polyunsaturated fatty acids (PUFAs), cyclooxygenase (COX) inhibitors, anti-TNFalpha and minocycline. Effectiveness and benefit/risk ratio of each class in MDD, bipolar disorders and schizophrenia was detailed when data were available. Several meta-analyses indicated effectiveness of PUFAs in MDD with a good tolerance profile. One meta-analysis indicated that COX-2 specific inhibitors showed effectiveness in schizophrenia. Anti-TNFalpha showed important effectiveness in resistant MDD with blood inflammatory abnormalities. Minocycline showed effectiveness in schizophrenia. CONCLUSION:Polyunsaturated fatty acids seem to have the best benefit/risk ratio profile but proved their effectiveness only in MDD. A number of anti-inflammatory drugs are available as adjunct treatment for treatment-resistant patients with MDD, schizophrenia and bipolar disorder. If used with caution regarding their possible side-effects, they may be reasonable therapeutic alternatives for resistant symptomatology.
Authors: Paulo L Lizano; Matcheri S Keshavan; Neeraj Tandon; Ian T Mathew; Suraj Sarvode Mothi; Debra M Montrose; Jeffrey K Yao Journal: Schizophr Res Date: 2015-12-11 Impact factor: 4.939
Authors: Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk Journal: Mol Neurobiol Date: 2015-05-02 Impact factor: 5.590
Authors: G Fond; N Resseguier; F Schürhoff; O Godin; M Andrianarisoa; L Brunel; E Bulzacka; B Aouizerate; F Berna; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; F Gabayet; C Lançon; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; M Leboyer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-11-10 Impact factor: 5.270
Authors: G Fond; O Godin; L Boyer; F Berna; M Andrianarisoa; N Coulon; L Brunel; E Bulzacka; B Aouizerate; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; S Leignier; C Lançon; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; P M Llorca; F Schürhoff; M Leboyer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-05-28 Impact factor: 5.270